Overview

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

Status:
Active, not recruiting
Trial end date:
2025-10-11
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Ono Pharmaceutical Co. Ltd
Treatments:
Antibodies, Monoclonal
Nivolumab